Back to Report Store Home

Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes

  • Published: Sep-2017
  • Report Code: GBIHC455MR
  • Report Format: pdf

Description

List of Tables

Table 1: Diabetes Drugs Market, Global, Approved Indications for Lantus, 2017

Table 2: Diabetes Drugs Market, Global, Approved Indications for Levemir, 2017

Table 3: Diabetes Drugs Market, Global, Approved Indications for Tresiba, 2017

Table 4: Diabetes Drugs Market, Global, Approved Indications for Toujeo, 2017

Table 5: Diabetes Drugs Market, Global, Approved Indications for Humalog, 2017

Table 6: Diabetes Drugs Market, Global, Approved Indications for Novolog, 2017

Table 7: Diabetes Drugs Market, Global, Approved Indications for Apidra, 2017

Table 8: Diabetes Drugs Market, Global, Approved Indications for Victoza, 2017

Table 9: Diabetes Drugs Market, Global, Approved Indications for Trulicity, 2017

Table 10: Diabetes Drugs Market, Global, Approved Indications for Januvia, 2017

Table 11: Diabetes Drugs Market, Global, Approved Indications for Galvus, 2017

Table 12: Diabetes Drugs Market, Global, Approved Indications for Tradjenta, 2017

Table 13: Diabetes Drugs Market, Global, Approved Indications for Invokana, 2017

Table 14: Diabetes Drugs Market, Global, Approved Indications for Jardiance, 2017

Table 15: Diabetes Drugs Market, Global, Approved Indications for Farxiga, 2017

Table 16: Diabetes Drugs Market, Global, Approved Indications for Soliqua, 2017

Table 17: Diabetes Drugs Market, Global, Approved Indications for Xultophy, 2017

Table 18: Diabetes Drugs Market, Global, Approved Indications for Janumet, 2017

Table 19: Market, Global, Approved Indications for Qtern, 2017

Table 20: Diabetes Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2016–2023 (Part 1)

Table 21: Diabetes Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2016–2023 (Part 2)

Table 22: Diabetes Drugs Market, Global, Generic Usage Across Key Indications, 2017

Table 23: Diabetes Drugs Market, Global, Annual Revenue within Diabetes by Company, 2016–2023

Table 24: Abbreviations

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards